Drag a card by its title · ⚙ to size, swap or remove

The company

Syndax Pharmaceuticals, Inc.

SNDX · Nasdaq

Health CareBiotechnologyNot moving yet

SNDX stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 13 weeks. It is 36.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 13
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $5.5M
Officials’ trades on record: 0
Institutions holding: 231 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months9

Buyers · sellers0 · 3

Who	Did	Shares	Traded
Michael A. MetzgerChief Executive Officer	sold	32,375at $24.24	8 Jul 2026filed 9 Jul 2026
Nicholas A.j. BotwoodHead of R&D, CMO	sold	31,235at $18.14	12 Jun 2026filed 12 Jun 2026
Nicholas A.j. BotwoodHead of R&D, CMO	sold	34,280at $18.00	11 Jun 2026filed 12 Jun 2026
Michael A. MetzgerChief Executive Officer	sold	6,847at $18.99	1 Jun 2026filed 2 Jun 2026
Keith A. GoldanChief Financial Officer	sold	1,177at $18.99	1 Jun 2026filed 2 Jun 2026
Keith A. GoldanChief Financial Officer	sold	3,410at $21.03	9 Feb 2026filed 10 Feb 2026
Michael A. MetzgerChief Executive Officer	sold	17,159at $21.03	9 Feb 2026filed 10 Feb 2026
Keith A. GoldanChief Financial Officer	sold	2,082at $20.62	6 Feb 2026filed 6 Feb 2026
Michael A. MetzgerChief Executive Officer	sold	7,412at $20.62	6 Feb 2026filed 6 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders231-2 on the quarter

New · exited38 · 40

Reported value$2.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
BlackRock, Inc.added · filed 7 Aug 2026	9,020,006$197.2M	+765,580+9.3%
Kynam Capital Management, LPunchanged · filed 14 Aug 2026	8,050,959$176.0M	00.0%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026	5,861,265$128.1M	+864,478+17.3%
STATE STREET CORPadded · filed 7 Aug 2026	5,658,424$123.7M	+1,228,348+27.7%
BANK OF AMERICA CORPreduced · filed 14 Aug 2026	4,045,094$88.4M	-204,742−4.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	3,927,892$85.9M	+105,313+2.8%
DEERFIELD MANAGEMENT COMPANY, L.P.unchanged · filed 14 Aug 2026	3,779,900$82.6M	00.0%
Eversept Partners, LPreduced · filed 14 Aug 2026	2,798,210$61.2M	-87,412−3.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	2,584,136$56.5M	+427,078+19.8%
Hood River Capital Management LLCadded · filed 14 Aug 2026	2,564,279$56.1M	+209,994+8.9%